The Impact of Extracellular Vesicle-Encapsulated Circulating MicroRNAs in Lung Cancer Research

Table 1

Circulating miRNAs as a potential biomarker for lung cancer.

Study design	Body fluid type	MicroRNA	Detection method	Reference
NSCLC versus normal	Serum	miR-25 and -223	NGS, qRT-PCR	[44]
NSCLC versus normal	Serum	miR-15b and -27b	qRT-PCR	[52]
NSCLC versus normal	Plasma vesicles	let-7f and miR-30e-3p	qRT-PCR array	[53]
Stage I/II versus IV NSCLC	Serum	miR-126 and -183	qRT-PCR	[54]
NSCLC versus normal	Plasma	miR-21, -126, -210, -486-5p	qRT-PCR	[55]
NSCLC versus normal	Sputum	miR-31, -210	qRT-PCR	[56]
NSCLC versus normal	Sputum	miR-31, -210	qRT-PCR	[57]
NSCLC versus normal; (metastasis stage)	Serum	miR-21	qRT-PCR	[60]
Prognosis of NSCLC	Serum	miR-486, -30d, -1, -499	NGS, qRT-PCR	[41]
Prognosis of NSCLC	Plasma	miR-221, -660, -486-5p, -28-3p, -197, -106a, -451, -140-5p, -16	qRT-PCR array	[58]
Prognosis of NSCLC	Serum	miR-21, -141, -200c	qRT-PCR	[59]
Response parameter for chemotherapy	Serum	miR-125b	qRT-PCR	[61]

NGS: next generation Solexa sequencing; qRT-PCR: quantitative real-time polymerase chain reaction; miR: microRNA; NSCLC: non-small-cell lung cancer.